IRB #

STUDY00020050

Title

A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to study the effects, good and bad, of the study drug NKTR 214 in combination with nivolumab on participants and their urothelial cancer.

Medical Condition(s)

chemotherapy in cisplatin ineligible, locally advanced or
metastatic urothelial

Eligibility Criteria

≥18 years old with metastatic urothelial or cisplatin ineligible urothelial carcinoma. Further labs, scans, and review of medical history will be done to confirm eligibility.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

For as long as the participant is seeing benefit from the study drug

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Nektar Therapuetics

Recruitment End

01/01/2021

Compensation Provided

No


Go Back